Total Payments
$23,627
2024 Payments
$3,501
Companies
86
Transactions
1,306
Medicare Patients
17,671
Medicare Billing
$2.7M
Payment Breakdown by Category
Food & Beverage$22,002 (93.1%)
Other$1,250 (5.3%)
Education$294.62 (1.2%)
Research$80.10 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $22,002 | 1,288 | 93.1% |
| Honoraria | $1,250 | 1 | 5.3% |
| Education | $294.62 | 16 | 1.2% |
| Unspecified | $80.10 | 1 | 0.3% |
Payments by Type
General
$23,547
1,305 transactions
Research
$80.10
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,970 | 99 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,588 | 130 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,547 | 89 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,471 | 80 | $0 (2024) |
| Genentech USA, Inc. | $1,363 | 99 | $0 (2024) |
| Epizyme, Inc., | $1,353 | 3 | $0 (2021) |
| Amgen Inc. | $1,170 | 62 | $0 (2023) |
| Janssen Biotech, Inc. | $1,055 | 63 | $0 (2024) |
| Celgene Corporation | $1,000 | 53 | $0 (2024) |
| PFIZER INC. | $867.44 | 58 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,501 | 162 | Novartis Pharmaceuticals Corporation ($392.15) |
| 2023 | $3,560 | 189 | Novartis Pharmaceuticals Corporation ($319.06) |
| 2022 | $3,136 | 176 | Merck Sharp & Dohme LLC ($323.54) |
| 2021 | $3,772 | 147 | Epizyme, Inc., ($1,353) |
| 2020 | $2,187 | 129 | Amgen Inc. ($316.30) |
| 2019 | $2,812 | 174 | Novartis Pharmaceuticals Corporation ($517.74) |
| 2018 | $2,523 | 163 | Novartis Pharmaceuticals Corporation ($432.30) |
| 2017 | $2,135 | 166 | Genentech USA, Inc. ($425.18) |
All Payment Transactions
1,306 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Oncology | ||||||
| 12/26/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: Genetically Defined Disease | ||||||
| 12/24/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $23.93 | General |
| Category: Oncology | ||||||
| 12/20/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $33.75 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.08 | General |
| 12/13/2024 | Cumberland Pharmaceuticals, Inc. | SANCUSO (Drug) | Food and Beverage | In-kind items and services | $13.94 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $26.18 | General |
| Category: Genetic Disease | ||||||
| 12/11/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $28.24 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $34.50 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $18.90 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.08 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 11/27/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $20.72 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Oncology | ||||||
| 11/22/2024 | GENZYME CORPORATION | ENJAYMO (Biological) | Food and Beverage | In-kind items and services | $32.96 | General |
| Category: Hematology | ||||||
| 11/21/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $18.92 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.29 | General |
| Category: Hematology | ||||||
| 11/18/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $22.90 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Genentech USA, Inc. | Itovebi (Biological), Perjeta, Phesgo | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: BioOncology | ||||||
| 11/14/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Incyte Corporation | MONJUVI (Drug), PEMAZYRE | Food and Beverage | Cash or cash equivalent | $17.74 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.52 | General |
| Category: Hematology | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $29.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | Eli Lilly and Company | $80.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 64 | 4,538 | 70,717 | $2.9M | $643,098 |
| 2022 | 65 | 4,686 | 87,444 | $2.9M | $616,516 |
| 2021 | 66 | 4,531 | 100,202 | $3.0M | $663,873 |
| 2020 | 60 | 3,916 | 90,957 | $2.8M | $730,189 |
Total Patients
17,671
Total Services
349,320
Medicare Billing
$2.7M
Procedure Codes
255
All Medicare Procedures & Services
255 procedure records from CMS Medicare Utilization — Page 1 of 11
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 48 | 10,860 | $455,100 | $200,087 | 44.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 243 | 757 | $189,250 | $68,411 | 36.1% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 30 | 3,700 | $222,925 | $60,715 | 27.2% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 14 | 732 | $607,560 | $52,816 | 8.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 393 | 654 | $114,450 | $39,195 | 34.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 53 | 394 | $190,696 | $33,690 | 17.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 73 | 122 | $42,090 | $15,427 | 36.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 457 | 1,475 | $110,625 | $15,015 | 13.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 18 | 11,700 | $54,522 | $14,824 | 27.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 92 | 291 | $37,830 | $13,221 | 34.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 468 | 1,524 | $114,300 | $11,386 | 10.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 465 | 1,306 | $39,180 | $10,637 | 27.1% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 24 | 575 | $43,125 | $9,543 | 22.1% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 20 | 24,480 | $73,440 | $9,343 | 12.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $25,245 | $8,389 | 33.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 49 | 351 | $63,180 | $7,006 | 11.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 143 | $34,177 | $6,028 | 17.6% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 391 | 752 | $56,400 | $4,424 | 7.8% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 175 | 330 | $28,050 | $4,356 | 15.5% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 16 | 176 | $22,880 | $4,350 | 19.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $13,260 | $4,126 | 31.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 28 | $13,720 | $3,693 | 26.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 84 | 343 | $25,725 | $3,597 | 14.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 51 | 311 | $23,325 | $3,338 | 14.3% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 208 | $9,360 | $3,120 | 33.3% |
About Dr. Richard Lee, MD
Dr. Richard Lee, MD is a Hematology & Oncology healthcare provider based in Knoxville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1316947385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Lee, MD has received a total of $23,627 in payments from pharmaceutical and medical device companies, with $3,501 received in 2024. These payments were reported across 1,306 transactions from 86 companies. The most common payment nature is "Food and Beverage" ($22,002).
As a Medicare-enrolled provider, Lee has provided services to 17,671 Medicare beneficiaries, totaling 349,320 services with total Medicare billing of $2.7M. Data is available for 4 years (2020–2023), covering 255 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Knoxville, TN
- Active Since 07/29/2005
- Last Updated 04/12/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1316947385
Products in Payments
- TAZVERIK (Drug) $1,353
- KEYTRUDA (Biological) $1,255
- OPDIVO (Biological) $1,167
- KISQALI (Drug) $728.94
- Lenvima (Drug) $552.59
- LIBTAYO (Biological) $524.19
- Enhertu (Drug) $519.87
- Revlimid (Drug) $489.76
- ADCETRIS (Biological) $424.82
- NINLARO (Drug) $383.77
- VENCLEXTA (Drug) $375.70
- DARZALEX (Biological) $372.53
- TASIGNA (Drug) $357.47
- VENCLEXTA (Biological) $342.15
- REBLOZYL (Biological) $329.92
- IMBRUVICA (Drug) $319.19
- JAKAFI (Drug) $314.37
- TAGRISSO (Drug) $313.29
- Perjeta (Biological) $313.27
- IBRANCE (Drug) $280.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Knoxville
Raymond Brig, Md, MD
Hematology & Oncology — Payments: $112,556
Hematology & Oncology $112,556
Dr. Daniel Ibach, Md, MD
Hematology & Oncology — Payments: $97,902
Hematology & Oncology $97,902
Ross Kerns, M.d, M.D
Hematology & Oncology — Payments: $46,740
Hematology & Oncology $46,740
Dr. Arun Kumar, Md, MD
Hematology & Oncology — Payments: $36,433
Hematology & Oncology $36,433
Nathan Schrock, Md, MD
Hematology & Oncology — Payments: $28,323
Hematology & Oncology $28,323
Tracy Dobbs, Md, MD
Hematology & Oncology — Payments: $28,019
Hematology & Oncology $28,019